Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01161654 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions
A NA study of Migraine, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01161654 is a NA study of Migraine that has completed, run by Roxane Laboratories. The registered enrollment target is 33 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01161654, a NA study of Migraine, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was to prove the bioequivalence of Naratriptan Hydrochloride Tablet under fed conditions.
Conditions Studied
Interventions
- DRUG naratriptan hydrochoride
Study Locations (1)
Washington
- Charles River Northwest Kinetics - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01161654
The ClinicalTrials.gov registry entry for NCT01161654 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (91% lower). The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which naratriptan hydrochoride is the first listed.
NCT01161654 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT01161654 about?
NCT01161654 is a clinical study titled "Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions". The objective of this study was to prove the bioequivalence of Naratriptan Hydrochloride Tablet under fed conditions.
What is the current status of trial NCT01161654?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2007-08. Estimated completion is 2007-09.
What conditions does trial NCT01161654 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT01161654?
The interventions under investigation include: naratriptan hydrochoride (DRUG).
Who is sponsoring clinical trial NCT01161654?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01161654 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Cocoa Extract for Migraine Trial
RECRUITING · NA
-
Migraine in Adolescents
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.